Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Ohio State University
mi
from
Columbus, OH
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
Ohio State University
mi
from
Columbus, OH
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Drexel University College of Medicine
mi
from
Philadelphia, PA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
Drexel University College of Medicine
mi
from
Philadelphia, PA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Medical University of South Carolina
mi
from
Charleston, SC
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
Medical University of South Carolina
mi
from
Charleston, SC
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Inova Fairfax
mi
from
Falls Church, VA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
Inova Fairfax
mi
from
Falls Church, VA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Sentara Heart Hospital
mi
from
Norfolk, VA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
Sentara Heart Hospital
mi
from
Norfolk, VA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
University of Washington Medical Center
mi
from
Seattle, WA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
University of Washington Medical Center
mi
from
Seattle, WA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Heart Clinics Northwest
mi
from
Spokane, WA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
Heart Clinics Northwest
mi
from
Spokane, WA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
The Vancouver Clinic
mi
from
Vancouver, WA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
The Vancouver Clinic
mi
from
Vancouver, WA
Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of a Single Dose of 1 mg Riociguat (BAY63-2521) on Myocardial Contractility and Relaxation in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (PH-sLVD)
Status: Archived
Clinical Trial Facility
mi
from
Boston, MA
Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of a Single Dose of 1 mg Riociguat (BAY63-2521) on Myocardial Contractility and Relaxation in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (PH-sLVD)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Boston, MA
Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of a Single Dose of 1 mg Riociguat (BAY63-2521) on Myocardial Contractility and Relaxation in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (PH-sLVD)
Status: Archived
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of a Single Dose of 1 mg Riociguat (BAY63-2521) on Myocardial Contractility and Relaxation in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (PH-sLVD)
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis
The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis
Status: Archived
Mayo Clinic College of Medicine
mi
from
Rochester, MN
The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis
The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis
Status: Archived
Updated: 1/1/1970
Mayo Clinic College of Medicine
mi
from
Rochester, MN
Clinical Trial to Assess the Early Effects of RVX000222 on the Changes of Lipid and Coronary Plaque in Patients With Recent Acute Coronary Syndrome
Phase II Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trials for the Assessment of Lipid and Coronary Plaque Changes With RVX000222 in Patients With Acute Coronary Syndrome Events
Status: Archived
West Shore Cardiology
mi
from
Muskegon, MI
Clinical Trial to Assess the Early Effects of RVX000222 on the Changes of Lipid and Coronary Plaque in Patients With Recent Acute Coronary Syndrome
Phase II Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trials for the Assessment of Lipid and Coronary Plaque Changes With RVX000222 in Patients With Acute Coronary Syndrome Events
Status: Archived
Updated: 1/1/1970
West Shore Cardiology
mi
from
Muskegon, MI
Same-Day Discharge After Coronary Percutaneous Transluminal Coronary Angioplasty (PTCA)
Feasibility and Safety of Same-Day Discharge of Troponin Negative Patients After Coronary PTCA Via the Transfemoral Approach
Status: Archived
Piedmont Hospital
mi
from
Atlanta, GA
Same-Day Discharge After Coronary Percutaneous Transluminal Coronary Angioplasty (PTCA)
Feasibility and Safety of Same-Day Discharge of Troponin Negative Patients After Coronary PTCA Via the Transfemoral Approach
Status: Archived
Updated: 1/1/1970
Piedmont Hospital
mi
from
Atlanta, GA
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
mi
from
Newington, CT
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Newington, CT
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
mi
from
Washington,
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Washington,
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
mi
from
Detroit, MI
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Detroit, MI
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
mi
from
Nashville, TN
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Nashville, TN
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Isovue in Peripheral Digital Subtraction Angiography
A Phase IV Multi-Center Study to Compare ISOVUE -250 and VISIPAQUE 270 for Motion Artifact and Pain in Peripheral Digital Subtraction Angiography (DSA)
Status: Archived
Bracco Diagnostics Inc
mi
from
Princeton, NJ
Isovue in Peripheral Digital Subtraction Angiography
A Phase IV Multi-Center Study to Compare ISOVUE -250 and VISIPAQUE 270 for Motion Artifact and Pain in Peripheral Digital Subtraction Angiography (DSA)
Status: Archived
Updated: 1/1/1970
Bracco Diagnostics Inc
mi
from
Princeton, NJ
Effect of Intermittent Pneumatic Compression on Ulcer Healing in Subjects With Secondary Lymphedema
Intermittent, Gradient, Pneumatic Compression Plus Standard Compression for Hard-To-Heal Venous Ulcers in Subjects With Secondary Lymphedema and Chronic Venous Insufficiency
Status: Archived
Center for Curative & Palliative Wound Care Calvary Hospital
mi
from
New York, NY
Effect of Intermittent Pneumatic Compression on Ulcer Healing in Subjects With Secondary Lymphedema
Intermittent, Gradient, Pneumatic Compression Plus Standard Compression for Hard-To-Heal Venous Ulcers in Subjects With Secondary Lymphedema and Chronic Venous Insufficiency
Status: Archived
Updated: 1/1/1970
Center for Curative & Palliative Wound Care Calvary Hospital
mi
from
New York, NY
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Johns Hopkins University
mi
from
Baltimore, MD
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
mi
from
Baltimore, MD
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Partners HealthCare
mi
from
Boston, MA
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Updated: 1/1/1970
Partners HealthCare
mi
from
Boston, MA
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
VA Boston Health Care System
mi
from
Boston, MA
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Updated: 1/1/1970
VA Boston Health Care System
mi
from
Boston, MA
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Case Western Reserve Univ
mi
from
Cleveland, OH
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
mi
from
Cleveland, OH
The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)
A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction
Status: Archived
University of Miami Hospital
mi
from
Miami, FL
The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)
A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction
Status: Archived
Updated: 1/1/1970
University of Miami Hospital
mi
from
Miami, FL
The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)
A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction
Status: Archived
Johns Hopkins University
mi
from
Baltimore, MD
The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)
A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
mi
from
Baltimore, MD
Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients
Utility of Chronic Cerebrospinal Venous Insufficiency Percutaneous Angioplasty for Multiple Sclerosis: The Albany Vascular Group Study
Status: Archived
The Vascular Group, PLLC
mi
from
Albany, NY
Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients
Utility of Chronic Cerebrospinal Venous Insufficiency Percutaneous Angioplasty for Multiple Sclerosis: The Albany Vascular Group Study
Status: Archived
Updated: 1/1/1970
The Vascular Group, PLLC
mi
from
Albany, NY
Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent?
Is Omega-3 Fatty Acid RBC Saturation Product Dependent?
Status: Archived
Bucci Laser Vision Institute
mi
from
Wilkes-Barre, PA
Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent?
Is Omega-3 Fatty Acid RBC Saturation Product Dependent?
Status: Archived
Updated: 1/1/1970
Bucci Laser Vision Institute
mi
from
Wilkes-Barre, PA
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Updated: 1/1/1970
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Vanderiblt University Medical Center
mi
from
Nashville, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Updated: 1/1/1970
Vanderiblt University Medical Center
mi
from
Nashville, TN
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Birmingham, AL
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Birmingham, AL
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Phoenix, AZ
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Phoenix, AZ
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Little Rock, AR
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Little Rock, AR
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
San Diego, CA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
San Diego, CA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Denver, CO
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Denver, CO
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
New Haven, CT
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
New Haven, CT
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Washington,
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Washington,
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Atlanta, GA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Atlanta, GA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Honolulu, HI
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Honolulu, HI
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Meridian, ID
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Meridian, ID
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Evanston, IL
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Evanston, IL
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Anderson, IN
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Anderson, IN